izuchukwu

A consultant at McKinsey is drafting the slides pitching this as we speak

Had the chance to see one of these in person - did not believe you could achieve “daylight indoors” before I did.

It was most likely Subset: https://news.ycombinator.com/item?id=36894939

It appears they are re-engineering their product, as they've taken down their sign up link and their landing page now advertises an upcoming, more traditional spreadsheet product: https://subset.so/

Their docs are still up, however, and has screenshots from their old infinite canvas spreadsheet product: https://docs.subset.so/

You should check out https://brev.dev. You can rent GPUs, pause instances, use your own AWS/GCP accounts to make use of your credits, and the CLI lets you use your GPU as if it’s on your local machine.

Check out the Creativity Faucet by Julian Shapiro. It’s a brief take on the same phenomenon: you’ve got to let the tap run and let the wastewater out before getting to the good stuff.

That’s because, in part, the good stuff is made out of identifying why the wastewater fell short.

https://www.julian.com/blog/creativity-faucet

If you want to get starting building with AI right away, I'd recommend getting an OpenAI key and playing with prompts in a tool like Everyprompt. Start asking it whatever you can think of, click Deploy to make an API out of it, then try building apps based on that.

You can then try running Stable Diffusion and using that in your apps too.

These other answers, while well meaning, are for building models and not for practically working with AI. They're like being given resources on how compilers work when someone asked how to write "Hello World."

Once you get that magic feeling of having something working, you can always dig into all of the research, like https://course.fast.ai, later.

If you've chosen the right data structures and organized things well, the interfaces will be self-evident too.

There are ways to specify schemas for JSON and XML. However, for APIs, XML's gone and schemas for JSON never caught on.

JSON is a serialized JS object, which itself is untyped, so anything can be in any order. Think NoSQL databases. This simplicity gave JSON the ability to be adopted by a multitude of languages very, very quickly. Foolish, maybe, but you could build Stripe on it.

GraphQL, an emerging API standard, does feature schemas, and its rise is bringing types back to APIs. It can be a bit more work to implement than JSON, though.

It's the classic complex-simple-complex pendulum swing. We're not done, either.

The computer doesn’t have to do these locally—there’s no reason this couldn’t be implemented as a thin client.

I agree that data has to be converted, but I don’t agree that it has to be as manual as it is today. Consider this: In addition to your API, a second JSON file gets generated that describes the schema of the first. On the consuming developer’s end, their language & IDE uses that schema to let you call APIs or RPCs exactly like they were local functions.

A big issue there is accessibility to a broader audience—something that Emacs and Lisp Machines don't quite have. Like you said, iOS Shortcuts is a very interesting example. You could say Internet-native automation tools like Zapier and Integromat fit the bill here too.

I wouldn't see potential maintenance or QA work as a deterrent to mainstream adoption. Users would underestimate it just like developers today do.

Listening to his recording of the subthalamic nucleus—as he describes it, "the sound of hundreds of thousands of your own neurons excitedly relaying the information they carry to one another fill[ing] the room"—was worth the read alone.

Highly recommend reading this post.

To the author: thank you for sharing, and I wish you a successful course of treatment.

Generational leaps emerge in the same ways everywhere.

For any space, if you provide a large enough net win for a large enough number of people, you introduce a generational leap. Very often, those people are completely new to the space.

The measure here isn’t how many growing companies that started with no-code adopt code as they grow. The measure here is how many growing companies that started with no-code wouldn’t have been started otherwise.

I’d keep an eye on the no-code movement.

Real leaps can be distinguished from hype by where the passion is coming from. The fact that the movement’s passion is coming from actual, paying users and not just no-code platform makers is key here.

It’s rapidly creating a new generation of software creators that could not create software before, and it’s improving very, very fast.

That’s very interesting to note. I imagine that the popularity of the iPod led a lot of new people to Limewire before the iTunes Store and Spotify took off, pushing its true peak to be a lot later than most (including myself) might recall.

The “Don’t steal music” label on every new iPod might as well have been a Limewire ad.

The article’s position comes down to “no fundamentally new way to program would make sense for today’s programmers to switch to it”, and gives examples like the platforms of the no-code movement.

From previous generational leaps, we’ve learned that the users post-leap don’t look like the pre-leap users at all. The iPod’s introduction brought about a generation of new digital music users that didn’t look like the Limewire generation, and the iPhone’s average user didn’t look like the average user of the BlackBerry before it.

Modern programming is at the core of HN, and of most of SV, sure. That said, we should still be the first to realize that a successful, fundamentally new way to program would target a new generation and idea of software maker, one that won’t look like the modern developer at all.

All good. I appreciate the perspective you’ve given!

This feels like the high-level missing piece in my understanding of its use. Do you know any resources that expand on QC’s effective potential more from this point of view?

Congrats on the launch, y’all. I’ve worked closely with Cyrus in the past and just met the team a few months ago. I’m very much looking forward to where this is going.

I’m not a doctor, this is very much not medical advice, and I’ve only been looking into these recently, but it does appear that the Benzimidazole class of medications from that recent cured-by-dog-dewormer post [0] like Albendazole and Mebendazole, both FDA approved as antihelmintics, do pass through the blood-brain barrier [1][2], and is currently used to that effect as a standard treatment for neurocysticercosis.

It appears a neurosurgery professor at Johns Hopkins that independently discovered the link was interested in it for that very reason [3].

[0]: https://news.ycombinator.com/item?id=20486893

[1]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874411/

[2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403762/

[3]: https://www.npr.org/sections/health-shots/2017/01/30/5124002...

Skepticism is very warranted here. And as I mention in your sibling comment, “promotes cancer recurrence” was a poor choice of term. “Permits,” due to the time between doses, would have been more accurate.

There are a lot of fly-by-night stories like this for a variety of reasons, be it ongoing research, funding seeking, or otherwise. I do believe the Benzimidazole class of medication mentioned is worth taking a deeper look at however—it seems to be a common thread over many of these.

Sometimes the reason something hasn’t seen use is more than the question of whether it’s clinically viable or not.

I appreciate any & all correction—I’m still learning myself.

I say toxic relative to the Benzimidazole family of medication, and though Paclitaxel’s worst side effects, like the neuropathy you mention, come cumulatively with chronic use, it’s more common side effects are still numerous, including a few serious ones, from sources I find.

And “promotes cancer recurrence” was a poor choice of term on my part. What I mean here is the time between doses is wide enough to permit recurrence in some cases.

Paclitaxel, an existing chemotherapy agent, kills cancer by interfering with microtubule dynamics in cells, the same way that Fenbendazole and other antihelmintics (dewormers) attack cancer in the recent post about someone curing themselves by taking OTC dog dewormer [0].

Unlike the dog dewormer, today’s Paclitaxel regimens are quite toxic. Interestingly, most of the toxicity comes from the method of delivery [1], not the drug itself. It’s actually why the way we give it (infrequent doses) actually promotes recurrence in some cases. This post talks about a much less toxic method of delivery, which explains why they can up the dose of the drug significantly while still being much safer.

[0]: https://news.ycombinator.com/item?id=20486893

[1]: https://en.m.wikipedia.org/wiki/Paclitaxel

It does appear that anti-cancer effects have been discovered in research in both Fenbendazole [0][1][2], the treatment that he used, as well as related anti-helmintics like Flubendazole [3], specifically when paired with certain vitamins like Vitamin E rather than when administered alone.

Flubendazole’s particularly interesting as it’s already FDA-approved for human use.

[0]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687140/ [1]: https://www.nature.com/articles/s41598-018-30158-6 [2]:https://www.ucsf.edu/news/2017/03/406321/deworming-pill-may-... [3]: https://www.ncbi.nlm.nih.gov/m/pubmed/25811972/

I’m first-generation and my family is Nigerian, and while I personally don’t eat the heads, we do entire dried fish quite a bit. Locally, we refer to it as “oporoko,” and it’s primarily imported from Norway, rather than Iceland, as another commenter has mentioned. It’s also very widely available in African and Nigerian food stores in the United States.

Similar to the what’s said in the link another commenter posted, I would say it is one of my favorite foods.